Last updated: February 20, 2026
What is NDC 00019-0952?
NDC 00019-0952 corresponds to Fingolimod (Brand name Gilenya), an immunomodulating drug approved for multiple sclerosis (MS) treatment. It is developed by Novartis and was first approved by the FDA in 2010.
Current Market Overview
Market Size
The multiple sclerosis (MS) treatment market was valued at approximately $22 billion in 2022, with fingolimod representing an estimated $1.2 billion share [1].
Competition
Fingolimod faces competition from other disease-modifying therapies (DMTs), including:
- Interferons (e.g., Avonex, Rebif)
- Other oral agents (e.g., dimethyl fumarate, teriflunomide)
- Monoclonal antibodies (e.g., ocrelizumab, natalizumab)
Fingolimod remains prominent due to its oral administration and efficacy profile.
Prescriber Trends
- Increasing preferred use of oral DMTs in place of injectables
- Growing patient compliance due to convenience
- Patent protections and recent biosimilar entries are critical factors influencing market dynamics
Price Analysis
Historical Pricing
- The average wholesale price (AWP) for Gilenya was approximately $4,500 per 30-day supply in 2022.
- Net pharmacy acquisition cost is generally lower, around $3,250 per month after discounts and rebates [2].
Price Trends
- The drug's price has adultually increased approximately 3-5% since its launch, reflecting inflation, manufacturing costs, and market demand.
- Patent exclusivity extends until at least 2029, limiting generic competition and maintaining high prices.
Price Projections (2023–2028)
| Year |
Estimated Wholesale Price per 30-day supply |
Key Factors |
| 2023 |
$4,600 |
Slight increase, market stability |
| 2024 |
$4,700 |
Inflation, potential new formulary restrictions |
| 2025 |
$4,850 |
Patent protections continue, limited competition |
| 2026 |
$4,950 |
Preparations for patent expiries, biosimilars increase |
| 2027 |
$5,050 |
Entry of biosimilar competitors, pressure on pricing |
| 2028 |
$5,150 |
Increased generic options, price erosion begins |
Future Market Dynamics
Patent Expiry and Generic Entry
- Patent expires around 2029; biosimilar or generic versions could reduce prices by 30–50% [3].
Regulatory and Policy Impact
- CMS and private insurers may negotiate prices downward.
- Value-based pricing models could influence future costs.
- Increased emphasis on cost-effectiveness may favor biosimilars.
Development Pipeline
- Several pipeline drugs aim to target MS, some offering oral options or improved safety profiles.
- Market share for fingolimod is expected to decline gradually once biosimilars enter.
Key Market Risks
- Potential patent litigation delays
- Regulatory challenges for biosimilar approvals
- Greater payer resistance to high prices
Investment and Business Considerations
- Monopolistic pricing persists until patent expiration
- Companies investing in biosimilar development could cut into market share post-2029
- Price stabilization is likely until biosimilars gain widespread approval
Summary
Fingolimod (NDC 00019-0952) maintains a high price point driven by patent protection, proven efficacy, and market dominance. Prices are projected to increase modestly until patent expiry in 2029, after which significant reductions are expected due to biosimilar competition.
Key Takeaways
- Current wholesale price stands at approximately $4,600 per month.
- Market size in MS drugs exceeds $20 billion, with fingolimod holding a notable share.
- Prices are likely to grow gradually until patent expiry, after which biosimilars could halve costs.
- Competitive dynamics and regulatory policies pose future risks and opportunities.
- Market entry of biosimilars post-2029 will significantly alter pricing and market share.
FAQs
1. When will fingolimod (Gilenya) face generic competition?
Patent protections expire around 2029, opening the market for biosimilars or generics.
2. How does fingolimod pricing compare to other MS therapies?
It is among the higher-priced oral DMTs, with similar pills costing around $3,500–$4,500 monthly; injectables tend to be cheaper but less preferred.
3. What factors could influence price reductions before patent expiry?
Insurance negotiations, formulary decisions, and healthcare policy adjustments may lower net costs.
4. Are biosimilar versions of fingolimod approved?
As of 2023, biosimilar versions are in development but not yet approved; their approval will impact pricing.
5. What is the potential impact of biosimilars on the MS market?
Biosimilars could reduce fingolimod's price by up to 50% and capture significant market share, affecting revenue projections.
References
[1] IQVIA. (2022). Global MS market data.
[2] Blue Book. (2023). Pharma Pricing and Reimbursement.
[3] FDA. (2023). Biosimilar Development and Approval Guidelines.
[4] MarketWatch. (2023). MS Drug Market Analysis.
